TPST|EPS -$6.33|Net Loss $26.3MTempest Therapeutics, Inc. reported a loss of $6.33 per share for the full year of 2025, as the clinical-stage biotechnology company continued advancing its pipeline of small molecule cancer therapeutics. The company posted a net loss of $26.3M for the year, reflecting the capital-intensive nature of early-stage drug development.
The Mill Valley, California-based firm focuses on developing small molecule treatments targeting various forms of cancer, a sector that typically requires substantial investment in clinical trials and regulatory processes before products can reach the market. Biotechnology companies at this stage of development commonly operate at a loss while building their portfolios and moving candidates through the clinical trial phases.
Despite the losses, Wall Street analysts maintain a largely positive stance on Tempest’s prospects. The consensus among analysts covering the stock stands at 4 buy ratings and 1 hold rating, with 0 sell recommendations. This bullish sentiment suggests that the investment community sees potential value in the company’s therapeutic pipeline and strategic direction.
Tempest trades on the NASDAQ under the ticker symbol TPST. The company remains focused on its clinical-stage programs as it works to advance its cancer treatment candidates through the development process.
This article was generated with the assistance of AI technology and reviewed for accuracy. AlphaStreet may receive compensation from companies mentioned in this article. This content is for informational purposes only and should not be considered investment advice.